Journal of Molecular Medicine

, Volume 97, Issue 1, pp 127–140 | Cite as

KIAA1199 promotes invasion and migration in non-small-cell lung cancer (NSCLC) via PI3K-Akt mediated EMT

  • Zhiyuan Tang
  • Yang Ding
  • Qin Shen
  • Caixin Zhang
  • Jun Li
  • Mohammed Nazar
  • Yan Wang
  • Xiaoyu ZhouEmail author
  • Jianfei HuangEmail author
Original Article


KIAA1199 is often upregulated in cancer cells, including non-small-cell lung cancer (NSCLC). Although KIAA1199 is associated with aggressive tumor phenotype and poor survival in NSCLC, little is known about its functional role in NSCLC progression. Using archived clinical samples, we evaluated KIAA1199 messenger RNA (mRNA) and protein expression in NSCLC tissues and correlated with NSCLC clinicopathological characteristics as well as overall survival. Using NSCLC cell lines, KIAA1199 was either silenced using gene-specific shRNA or overexpressed to assess the impact on EMT signaling pathways. Finally, in a mouse xenograft NSCLC model, we determine the therapeutic potential of KIAA1199 repression. Our data showed that KIAA1199 was significantly upregulated in NSCLC tissues compared to adjacent normal tissues both at the mRNA (P < 0.001) and protein levels (P < 0.05). KIAA1199 overexpression is an independent prognostic marker for overall survival (HR = 1.833). In NSCLC cell lines, KIAA1199 expression directly influences the expression of EMT markers, EMT-inducing transcription factors (EMT-TFs), and EMT signaling molecules. Knocking down of KIAA1199 expression in the mouse NSCLC xenograft model significantly suppressed tumor growth and augmented the efficacy of chemotherapy (n = 5; P < 0.05). We conclude that KIAA1199 is not only a prognostic marker but a novel therapeutic target in NSCLC through regulating EMT signaling pathway.

Key messages

  • KIAA1199 overexpression is an independent prognostic marker in NSCLC.

  • KIAA1199 expression directly influences the expression of EMT markers.

  • KIAA1199 promotes invasion and migration in NSCLC via PI3K-Akt mediated EMT.


KIAA1199 NSCLC Metastasis 



Non-small-cell lung cancer


Cell migration-inducing and hyaluronan-binding protein


Human Unidentified Gene-Encoded


Cell Bank, Type Culture Collection, Chinese Academy of Science


Epithelial-mesenchymal transition


EMT-inducing transcription factors


Overall survival




Standard deviation


Fetal bovine serum




Tissue microarray


Enhanced chemiluminescence


Standard deviation


Tumor node metastasis


Hazard ratio


Confidence interval


High-density lipoprotein


Reconstituted high-density lipoprotein



We thank the members of Clinical Biobank of the Affiliated Hospital of Nantong University.

Authors’ contributions

Z.T. and Y.D. performed the basic experiments and analyzed the data. Q.S. and C.Z. acquired the clinical data. X.Z. and J.H. conceived the project and designed the study. J.L. and Y.W. analyzed the results. Z.T. and M.N. wrote the manuscript.

Funding information

This work was supported by Key Technology Research of Nantong-People’s Livelihood (No. MS22015114), National Natural Science Foundation of China (No. 81503143), and Six Talent Peaks Project in Jiangsu Province (No. 2015-WSW-049).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest.

Ethics approval and consent to participate

All animal experiments carried out in this project were following the NIH Guidelines with the ethical approval of the Administration Committee of Experimental Animals, Jiangsu Province, China.

Supplementary material

109_2018_1721_Fig6_ESM.png (1.2 mb)
Supplementary Fig. 1

Schematic illustration of rHDL/Sh-KIAA1199 nanoparticles. a. sh-KIAA1199 was encapsulated with cationic lipid DOTAP. The complexes were loaded into rHDL to construct the gene-loaded nanoparticles by thin-film dispersion method; b, c. Graphical representation of the particle size and zeta potential of polyplexes. (PNG 1226 kb)

109_2018_1721_MOESM1_ESM.tif (2.1 mb)
High Resolution Image (TIF 2197 kb)
109_2018_1721_Fig7_ESM.png (1.8 mb)
Supplementary Fig. 2

KIAA1199 regulates migration in NSCLC cell lines. a and b. Silencing KIAA1199 by shRNA-3 reduced cell migration by Transwell assay in A549 and H1299 cell lines respectively; c and d. Overexpression of KIAA1199 increased cell migration by Transwell assay in H1975 and H1650 cell line respectively; e, f, g and h. Cell invasion assay by silencing KIAA1199 with shRNA-1 in A549 and H1299 cell lines. Data are presented as means ± SD; n = 5–8/group. * P < 0.05, ** P < 0.01, versus Control. (PNG 1834 kb)

109_2018_1721_MOESM2_ESM.tif (3.9 mb)
High Resolution Image (TIF 4023 kb)


  1. 1.
    Fitzmaurice C, Dicker D, Pain A et al (2015) The global burden of cancer 2013. JAMA Oncol 1(4):505–527CrossRefGoogle Scholar
  2. 2.
    Fitzmaurice C, Allen C, Barber RM et al (2017) Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol 3(4):524–548CrossRefGoogle Scholar
  3. 3.
    Chen W, Zheng R, Baade PD et al (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66(2):115–132CrossRefGoogle Scholar
  4. 4.
    Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA (2008) Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83(5):584–594CrossRefGoogle Scholar
  5. 5.
    Tas F, Ciftci R, Kilic L, Karabulut S (2013) Age is a prognostic factor affecting survival in lung cancer patients. Oncol Lett 6(5):1507–1513CrossRefGoogle Scholar
  6. 6.
    Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68(1):7–30CrossRefGoogle Scholar
  7. 7.
    Brabletz T, Kalluri R, Nieto MA, Weinberg RA (2018) EMT in cancer. Nat Rev Cancer 18:128–134CrossRefGoogle Scholar
  8. 8.
    Kim DH, Xing T, Yang Z, Dudek R, Lu Q, Chen YH (2017) Epithelial mesenchymal transition in embryonic development, tissue repair and cancer: a comprehensive overview. J Clin Med 7Google Scholar
  9. 9.
    Otsuki Y, Saya H, Arima Y (2017) Prospects for new lung cancer treatments that target EMT signaling. Dev Dyn 247:462–472CrossRefGoogle Scholar
  10. 10.
    Zhang Y, Jia S, Jiang WG (2014) KIAA1199 and its biological role in human cancer and cancer cells (review). Oncol Rep 31(4):1503–1508CrossRefGoogle Scholar
  11. 11.
    Rizzolio S, Battistini C, Cagnoni G et al. (2017) Downregulating neuropilin-2 triggers a novel mechanism enabling EGFR-dependent resistance to oncogene-targeted therapies. Cancer Res 78:1058–1068CrossRefGoogle Scholar
  12. 12.
    Deng F, Lei J, Zhang X, Huang W, Li Y, Wu D (2017) Overexpression of KIAA1199: an independent prognostic marker in nonsmall cell lung cancer. J Cancer Res Ther 13(4):664–668CrossRefGoogle Scholar
  13. 13.
    Jia S, Qu T, Wang X et al (2017) KIAA1199 promotes migration and invasion by Wnt/β-catenin pathway and MMPs mediated EMT progression and serves as a poor prognosis marker in gastric cancer. PLoS One 12(4):e0175058CrossRefGoogle Scholar
  14. 14.
    Shostak K, Zhang X, Hubert P et al (2014) NF-κB-induced KIAA1199 promotes survival through EGFR signalling. Nat Commun 5:5232CrossRefGoogle Scholar
  15. 15.
    McMahon KM, Thaxton CS (2014) High-density lipoproteins for the systemic delivery of short interfering RNA. Expert Opin Drug Deliv 11(2):231–247CrossRefGoogle Scholar
  16. 16.
    Detre S, Saclani JG, Dowsett M (1995) A “quickscore” method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol 48(9):876–878CrossRefGoogle Scholar
  17. 17.
    Huang J, Mei H, Tang Z et al (2017) Triple-amiRNA VEGFRs inhibition in pancreatic cancer improves the efficacy of chemotherapy through EMT regulation. J Control Release 245:1–14CrossRefGoogle Scholar
  18. 18.
    Huang J, Fan X, Wang X et al (2015) High ROR2 expression in tumor cells and stroma is correlated with poor prognosis in pancreatic ductal adenocarcinoma. Sci Rep 5:12991CrossRefGoogle Scholar
  19. 19.
    Liu X, Xu Y, Jin Q et al (2016) EphA8 is a prognostic marker for epithelial ovarian cancer. Oncotarget 7(15):20801–20809Google Scholar
  20. 20.
    Kikuno R, Nagase T, Nakayama M et al (2004) HUGE: a database for human KIAA proteins, a 2004 update integrating HUGEppi and ROUGE. Nucleic Acids Res 32(Database issue):D502–D504CrossRefGoogle Scholar
  21. 21.
    Abe S, Usami S, Nakamura Y (2003) Mutations in the gene encoding KIAA1199 protein, an inner-ear protein expressed in Deiters’ cells and the fibrocytes, as the cause of nonsyndromic hearing loss. J Hum Genet 48(11):564–570CrossRefGoogle Scholar
  22. 22.
    Yoshida H, Nagaoka A, Kusaka-Kikushima A et al (2013) KIAA1199, a deafness gene of unknown function, is a new hyaluronan binding protein involved in hyaluronan depolymerization. Proc Natl Acad Sci U S A 110(14):5612–5617CrossRefGoogle Scholar
  23. 23.
    Shimoda M, Yoshida H, Mizuno S et al (2017) Hyaluronan-binding protein involved in hyaluronan depolymerization controls endochondral ossification through hyaluronan metabolism. Am J Pathol 187(5):1162–1176CrossRefGoogle Scholar
  24. 24.
    Nagaoka A, Yoshida H, Nakamura S et al (2015) Regulation of hyaluronan (HA) metabolism mediated by HYBID (Hyaluronan-binding protein involved in HA Depolymerization, KIAA1199) and HA synthases in growth factor-stimulated fibroblasts. J Biol Chem 290(52):30910–30923CrossRefGoogle Scholar
  25. 25.
    Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2(7):489–501CrossRefGoogle Scholar
  26. 26.
    Evensen NA, Li Y, Kuscu C et al (2015) Hypoxia promotes colon cancer dissemination through up-regulation of cell migration-inducing protein (CEMIP). Oncotarget 6(24):20723–20739CrossRefGoogle Scholar
  27. 27.
    Fink SP, Myeroff LL, Kariv R et al (2015) Induction of KIAA1199/CEMIP is associated with colon cancer phenotype and poor patient survival. Oncotarget 6(31):30500–30515CrossRefGoogle Scholar
  28. 28.
    Xu J, Liu Y, Wang X et al (2015) Association between KIAA1199 overexpression and tumor invasion, TNM stage, and poor prognosis in colorectal cancer. Int J Clin Exp Pathol 8(3):2909–2918Google Scholar
  29. 29.
    Jami MS, Hou J, Liu M et al (2014) Functional proteomic analysis reveals the involvement of KIAA1199 in breast cancer growth, motility and invasiveness. BMC Cancer 14:194CrossRefGoogle Scholar
  30. 30.
    Evensen NA, Kuscu C, Nguyen HL et al (2013) Unraveling the role of KIAA1199, a novel endoplasmic reticulum protein, in cancer cell migration. J Natl Cancer Inst 105(18):1402–1416CrossRefGoogle Scholar
  31. 31.
    Suh HN, Jun S, Oh AY et al (2016) Identification of KIAA1199 as a biomarker for pancreatic intraepithelial neoplasia. Sci Rep 6:38273CrossRefGoogle Scholar
  32. 32.
    Koga A, Sato N, Kohi S et al (2017) KIAA1199/CEMIP/HYBID overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma. Pancreatology 17(1):115–122CrossRefGoogle Scholar
  33. 33.
    Zhang D, Zhao L, Shen Q et al (2017) Down-regulation of KIAA1199/CEMIP by miR-216a suppresses tumor invasion and metastasis in colorectal cancer. Int J Cancer 140(10):2298–2309CrossRefGoogle Scholar
  34. 34.
    Kohi S, Sato N, Koga A, Matayoshi N, Hirata K (2017) KIAA1199 is induced by inflammation and enhances malignant phenotype in pancreatic cancer. Oncotarget 8(10):17156–17163CrossRefGoogle Scholar
  35. 35.
    Li L, Yan LH, Manoj S, Li Y, Lu L (2017) Central role of CEMIP in tumorigenesis and its potential as therapeutic target. J Cancer 8(12):2238–2246CrossRefGoogle Scholar
  36. 36.
    Thiery JP, Acloque H, Huang RY, Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139:871–890CrossRefGoogle Scholar
  37. 37.
    Peinado H, Olmeda D, Cano A (2007) Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype. Nat Rev Cancer 7:415–428CrossRefGoogle Scholar
  38. 38.
    Shahzad MM, Mangala LS, Han HD et al (2011) Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. Neoplasia 13(4):309–319CrossRefGoogle Scholar
  39. 39.
    Ding Y, Wang W, Feng M et al (2012) A biomimetic nanovector-mediated targeted cholesterol-conjugated siRNA delivery for tumor gene therapy. Biomaterials 33(34):8893–8905CrossRefGoogle Scholar
  40. 40.
    Ding Y, Wang Y, Zhou J et al (2014) Direct cytosolic siRNA delivery by reconstituted high density lipoprotein for target-specific therapy of tumor angiogenesis. Biomaterials 35(25):7214–7227CrossRefGoogle Scholar
  41. 41.
    Xu W, Yang Z, Lu N (2015) A new role for the PI3K/Akt signaling pathway in the epithelial-mesenchymal transition. Cell Adhes Migr 9:317–324CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Zhiyuan Tang
    • 1
    • 2
  • Yang Ding
    • 3
  • Qin Shen
    • 2
  • Caixin Zhang
    • 2
  • Jun Li
    • 2
  • Mohammed Nazar
    • 2
  • Yan Wang
    • 4
  • Xiaoyu Zhou
    • 2
    Email author
  • Jianfei Huang
    • 1
    • 5
    Email author
  1. 1.Department of Clinical BiobankNantong University Affiliated HospitalNantongChina
  2. 2.Department of Respiratory MedicineAffiliated Hospital of Nantong UniversityNantongChina
  3. 3.State Key Laboratory of Natural Medicines, Department of PharmaceuticsChina Pharmaceutical UniversityNanjingChina
  4. 4.Department of Emergency MedicineAffiliated Hospital of Nantong UniversityNantongChina
  5. 5.Department of PathologyNantong University Affiliated HospitalNantongChina

Personalised recommendations